NCT05776108View on ClinicalTrials.gov

A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 23, 2023

Primary Completion Date

June 8, 2023

Study Completion Date

June 8, 2023

Conditions
HIV Infections
Interventions
DRUG

Cabotegravir IR Formulation (reference)

Cabotegravir IR Formulation (reference) will be administered.

DRUG

Cabotegravir DT Formulation (test 1)

Cabotegravir DT Formulation (test 1) will be administered.

DRUG

Cabotegravir DT Formulation (test 2)

Cabotegravir DT Formulation (test 2) will be administered.

Trial Locations (1)

78744

GSK Investigational Site, Austin

Sponsors

Lead Sponsor

ViiV Healthcare
All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY

NCT05776108 - A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation | Biotech Hunter | Biotech Hunter